RESUMO
BACKGROUND Neonatal acute leukemia is a rare condition. Little is known about its incidence and outcomes, and treatment options have not been standardized. CASE REPORT A 3-day old, apparently healthy male newborn was referred to the pediatric intensive care unit with multiple violaceous macules and a few papules on his face and upper trunk. After initial spontaneous regression, the lesions reappeared. Skin biopsy and bone marrow aspirate revealed a diagnosis of acute lymphoblastic leukemia (ALL). ALL induction therapy was initiated on day 24, resulting in morphological remission at the end of induction therapy. ALL chemotherapy was guided by sequential PCR-based monitoring of minimal residual disease (MRD). The patient received a transplant from an unrelated HLA high-resolution matched (10/10 loci) permissive donor. He was followed-up after transplant conducted by sequential PCR-based measurements of MRD in bone marrow. CONCLUSIONS Neonatal leukemia often presents as congenital skin lesions known as blueberry muffin rash. ALL induction therapy was started at the end of the neonatal period. Treatment was well-tolerated and effective. Early donor search and PCR-MRD guided treatment surveillance can help to achieve and maintain molecular remission.
Assuntos
Transplante de Células-Tronco Hematopoéticas , Leucemia-Linfoma Linfoblástico de Células Precursoras , Criança , Feminino , Seguimentos , Humanos , Quimioterapia de Indução , Lactente , Recém-Nascido , Masculino , Neoplasia Residual , Reação em Cadeia da Polimerase , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Gravidez , Indução de Remissão , Transplante Homólogo , Doadores não RelacionadosRESUMO
Scleroderma is a heterogeneous group of fibrosing connective tissue disorders of unknown etiology. Morphea is a localized form of scleroderma that occasionally leads to chronic erosions and ulcerations of the skin. Fibrosis, inflammation and chronic ulcerations may eventually promote skin neoplasms; morphea is therefore a rare but established risk factor for cutaneous squamous cell carcinoma (cSCC). We present a review of 16 scleroderma patients: 15 case reports from the literature (identified by a PubMed search) and one case from our clinic of a patient who had developed cSCC, and we discuss potential underlying mechanisms. Statistical analysis revealed that the lower extremities were the body site most commonly affected by cSCC in these scleroderma patients. The mean time interval between the onset of scleroderma and the development of cSCC was ten to twenty years. In patients with morphea, we recommend checking for skin tumors during follow-up examinations as well as a careful risk-benefit analysis when considering the application of immunosuppressants or phototherapy in view of their potential carcinogenic side effects.
Assuntos
Carcinoma de Células Escamosas/etiologia , Esclerodermia Localizada/complicações , Neoplasias Cutâneas/etiologia , Adolescente , Adulto , Idade de Início , Idoso , Carcinoma de Células Escamosas/patologia , Feminino , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Fototerapia/efeitos adversos , Fatores de Risco , Esclerodermia Localizada/patologia , Esclerodermia Localizada/terapia , Neoplasias Cutâneas/patologia , Adulto JovemRESUMO
The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recommendations for use and treatment algorithms. Other aspects addressed herein include vaccinations in children and adolescents with psoriasis as well as various disease subtypes such as guttate psoriasis, diaper psoriasis, pustular psoriasis and psoriatic arthritis. Finally, we also provide recommendations for imaging studies and the diagnostic workup to rule out tuberculosis prior to initiating systemic treatment. Note: This article constitutes part 1 of the Sk2 guidelines for the treatment of psoriasis in children and adolescents. Part 2 will be published in the next issue. It contains chapters on UV therapy, systemic treatment, tonsillectomy and antibiotics, vaccinations, guttate psoriasis, psoriatic arthritis, complementary medicine, as well as imaging studies and diagnostic workup to rule out tuberculosis prior to systemic treatment.
Assuntos
Guias de Prática Clínica como Assunto/normas , Psoríase/tratamento farmacológico , Psoríase/patologia , Administração Tópica , Adolescente , Artrite Psoriásica/diagnóstico , Criança , Pré-Escolar , Comorbidade , Consenso , Dermatologia , Humanos , Lactente , Recém-Nascido , Uso Off-Label/estatística & dados numéricos , Psoríase/psicologia , Psoríase/radioterapia , Qualidade de Vida/psicologia , Reumatologia , Índice de Gravidade de Doença , Raios UltravioletaRESUMO
The essential trace element zinc (Zn) plays a key role in the development, differentiation and growth of various human tissues. Zinc homeostasis is primarily regulated by two zinc transporter families (solute-linked carrier families, SLC). Disturbances in zinc metabolism may give rise to disorders that typically manifest themselves on the skin. An autosomal recessive zinc deficiency disorder, acrodermatitis enteropathica is caused by a mutation in the gene coding for the ZIP4 transporter. Due to intestinal malabsorption, affected infants develop clinical signs and symptoms shortly after weaning. Acquired zinc deficiency is a rare but underdiagnosed disorder associated with various etiologies and variable clinical manifestations. Depending on the patient's age, a multitude of causes have to be considered. Given the characteristic periorificial and acral lesions, the clinical diagnosis is usually made by dermatologists. Laboratory confirmation includes measurement of plasma zinc levels and - as a supplementary measure - zinc-dependent enzymes such as alkaline phosphatase. Oral zinc replacement therapy frequently leads to clinical remission within a few days. Depending on the cause, disease management should include cooperation with pediatricians and gastroenterologists in order to guarantee optimal patient care.
Assuntos
Dermatopatias/etiologia , Zinco/fisiologia , Acrodermatite/etiologia , Acrodermatite/patologia , Criança , Pré-Escolar , Diagnóstico Diferencial , Doenças do Cabelo/etiologia , Humanos , Lactente , Síndromes de Malabsorção/complicações , Dermatopatias/patologia , Cicatrização/fisiologia , Zinco/deficiênciaAssuntos
Hemangioma/congênito , Doenças do Prematuro/terapia , Neoplasias Cutâneas/congênito , Criança , Pré-Escolar , Terapia Combinada , Estudos Transversais , Criocirurgia , Diagnóstico Diferencial , Relação Dose-Resposta a Droga , Estética , Feminino , Hemangioma/diagnóstico , Hemangioma/terapia , Humanos , Lactente , Recém-Nascido , Doenças do Prematuro/diagnóstico , Terapia com Luz de Baixa Intensidade , Masculino , Prednisolona/administração & dosagem , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/terapia , SíndromeRESUMO
In about one third of patients, psoriasis starts in the first or second decade of life. In the beginning, involvement is often atypical or mild, and a confident diagnosis may be difficult to establish. Plaque psoriasis is the most frequent type, also in children, but lesions are often smaller, thinner, and less scaly than in adults. Treatment can be a challenge because many therapeutic options have drawbacks or are not approved in childhood. Because psoriasis is a life-long disease, affected children and their parents need special support and guidance. We herein focus on the peculiarities of clinical presentations and of the management of psoriatic children and adolescents.
Assuntos
Psoríase , Adolescente , Corticosteroides/uso terapêutico , Criança , Colecalciferol/análogos & derivados , Colecalciferol/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Diagnóstico Diferencial , Humanos , Imunossupressores/uso terapêutico , Ceratolíticos/uso terapêutico , Fototerapia , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Psoríase/fisiopatologia , Psoríase/terapia , Fatores de RiscoRESUMO
BACKGROUND: Recently, it has been shown that UVB phototherapy may be more effective than UVA in the treatment of vitiligo. Currently, however, no studies have compared the efficacy of UVB311 nm and broad-band UVB therapy. Calcipotriol has recently been reported to be effective adjunctive treatment for vitiligo, enhancing the efficacy of 8-methoxypsoralen plus UVA (PUVA) therapy. METHODS: Ten patients were enrolled in the study; nine completed the 12 months of therapy. The upper part of the body was treated twice weekly with UVB311 nm and the lower part with broad-band UVB. Calcipotriol was applied onto the vitiligo lesions of the right side of the body and placebo on the left side. Repigmentation was documented by photography, planimetry, and Vitiligo Disease Activity (VIDA) score. The quality of life was measured by the Dermatology Life Quality Index (DLQI). RESULTS: After 7-16 weeks, six of the nine patients showed initial repigmentation on the side treated with UVB311 nm. After 6 months of treatment, none of the patients showed repigmentation on the areas treated with broad-band UVB, which prompted us to apply UVB311 nm all over the body. At the end of 12 months, two patients showed > 75% repigmentation, two showed 51-75%, two showed 26-50%, and three showed 0-25%. In all patients with progressive vitiligo (seven of the nine patients), disease activity was stopped. Remarkably, vitiligo lesions treated with calcipotriol initially showed delayed repigmentation compared with control areas; however, there was no therapeutic difference between calcipotriol and placebo, both in combination with UVB311 nm, by the end of the study. The DLQI score improved significantly by an average of 28%. Conclusion UVB311 nm therapy was effective in the treatment of vitiligo, whereas broad-band UVB had no effect. Combination with calcipotriol ointment was not superior to UVB311 nm monotherapy. The quality of life significantly improved with narrow-band UVB311 nm phototherapy.